Incysus Therapeutics to Present at the 2020 BIO CEO & Investor Conference
07 févr. 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Announces Issuance of Foundational U.S. Patent Covering Use of Drug Resistant Immunotherapy (DRI) Technology for the Treatment of Cancer
29 janv. 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Participate in Evercore ISI HealthCONx Conference
26 nov. 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at the New York Oncology Investor Conference
07 nov. 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at 5th Annual CAR-TCR Summit
10 sept. 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...